Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Grignani

Showing results (551-560 of 688) with videos related to

Pageof 69
Sort By:
Journal of Immunotherapy (Hagerstown, Md. : 1997)|August 16, 2012
Ex vivo allogeneic stimulation significantly improves expansion of cytokine-induced killer cells without increasing their alloreactivity across HLA barriersMaja Todorovic, Giulia Mesiano, Loretta Gammaitoni, et al.
Physics in Medicine and Biology|November 26, 2025
First multi-institutional systematic comparison of the neutron ambient dose equivalent produced by proton therapy systemsArash Darafsheh, Yao Hao, Anissa Bey, et al.
BMC Cancer|May 9, 2015
The combination of sorafenib and everolimus shows antitumor activity in preclinical models of malignant pleural mesotheliomaYmera Pignochino, Carmine Dell'Aglio, Simona Inghilleri, et al.
Cancer Immunology, Immunotherapy : CII|December 23, 2025
Correction: Development and activity of canine B7-H3-CAR.CIK lymphocytes against sarcomas: preclinical evidence and perspectives for human clinical translationRaffaella De Maria, Chiara Donini, Sonia Capellero, et al.
British Journal of Cancer|July 31, 2018
A phase II randomised (calibrated design) study on the activity of the single-agent trabectedin in metastatic or locally relapsed uterine leiomyosarcomaAngiolo Gadducci, Federica Grosso, Giovanni Scambia, et al.
Cancer Immunology, Immunotherapy : CII|September 23, 2025
The cGAS-STING pathway is a master regulator of OCT4 expression in persistent sarcoma cells and enhances cellular immunotherapy with NK and CIK lymphocytesGiorgia Giordano, Alessandra Merlini, Federica Capozzi, et al.
Cancer|May 19, 2012
Tumor response assessment by modified Choi criteria in localized high-risk soft tissue sarcoma treated with chemotherapySilvia Stacchiotti, Paolo Verderio, Antonella Messina, et al.
Cancer Immunology, Immunotherapy : CII|September 13, 2025
Development and activity of canine B7-H3-CAR.CIK lymphocytes against sarcomas: preclinical evidence and perspectives for human clinical translationRaffaella De Maria, Chiara Donini, Sonia Capellero, et al.
Cancers|October 16, 2024
Phase I Clinical Trial on Pleural Mesothelioma Using Neoadjuvant Local Administration of Paclitaxel-Loaded Mesenchymal Stromal Cells (PACLIMES Trial): Study Rationale and DesignGiulia Maria Stella, Daniela Lisini, Paolo Pedrazzoli, et al.
European Journal of Surgical Oncology : the Journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology|March 22, 2025
Sarcopenia is a negative prognostic factor in localized extremities/trunk wall soft tissue sarcomasTiziana Robba, Vito Chianca, Martina Rabino, et al.
Pageof 69

Showing results (551-560 of 688) with videos related to

Sort By:
Pageof 69
Journal of Immunotherapy (Hagerstown, Md. : 1997)|August 16, 2012
Ex vivo allogeneic stimulation significantly improves expansion of cytokine-induced killer cells without increasing their alloreactivity across HLA barriersMaja Todorovic, Giulia Mesiano, Loretta Gammaitoni, et al.
Physics in Medicine and Biology|November 26, 2025
First multi-institutional systematic comparison of the neutron ambient dose equivalent produced by proton therapy systemsArash Darafsheh, Yao Hao, Anissa Bey, et al.
BMC Cancer|May 9, 2015
The combination of sorafenib and everolimus shows antitumor activity in preclinical models of malignant pleural mesotheliomaYmera Pignochino, Carmine Dell'Aglio, Simona Inghilleri, et al.
Cancer Immunology, Immunotherapy : CII|December 23, 2025
Correction: Development and activity of canine B7-H3-CAR.CIK lymphocytes against sarcomas: preclinical evidence and perspectives for human clinical translationRaffaella De Maria, Chiara Donini, Sonia Capellero, et al.
British Journal of Cancer|July 31, 2018
A phase II randomised (calibrated design) study on the activity of the single-agent trabectedin in metastatic or locally relapsed uterine leiomyosarcomaAngiolo Gadducci, Federica Grosso, Giovanni Scambia, et al.
Cancer Immunology, Immunotherapy : CII|September 23, 2025
The cGAS-STING pathway is a master regulator of OCT4 expression in persistent sarcoma cells and enhances cellular immunotherapy with NK and CIK lymphocytesGiorgia Giordano, Alessandra Merlini, Federica Capozzi, et al.
Cancer|May 19, 2012
Tumor response assessment by modified Choi criteria in localized high-risk soft tissue sarcoma treated with chemotherapySilvia Stacchiotti, Paolo Verderio, Antonella Messina, et al.
Cancer Immunology, Immunotherapy : CII|September 13, 2025
Development and activity of canine B7-H3-CAR.CIK lymphocytes against sarcomas: preclinical evidence and perspectives for human clinical translationRaffaella De Maria, Chiara Donini, Sonia Capellero, et al.
Cancers|October 16, 2024
Phase I Clinical Trial on Pleural Mesothelioma Using Neoadjuvant Local Administration of Paclitaxel-Loaded Mesenchymal Stromal Cells (PACLIMES Trial): Study Rationale and DesignGiulia Maria Stella, Daniela Lisini, Paolo Pedrazzoli, et al.
European Journal of Surgical Oncology : the Journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology|March 22, 2025
Sarcopenia is a negative prognostic factor in localized extremities/trunk wall soft tissue sarcomasTiziana Robba, Vito Chianca, Martina Rabino, et al.
Pageof 69